Therapy Areas
Novavax makes one million doses of protein-based COVID-19 vaccine available in UK
27 September 2022 -

Biotechnology company Novavax Inc (Nasdaq:NVAX) announced on Tuesday that an initial one million doses of its COVID-19 vaccine Nuvaxovid are now available for use in the UK.

Nuvaxovid is the first protein-based COVID-19 vaccine to be authorised by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and will be offered in accordance with advice from the Joint Committee on Vaccination and Immunisation (JCVI).

The vaccine was created using Novavax's recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and is formulated with Novavax's patented saponin-based Matrix-M adjuvant to enhance the immune response.

The MHRA granted Conditional Marketing Authorisation (CMA) for Nuvaxovid's use as a two-dose primary series vaccine for active immunisation to prevent COVID-19 in adults aged 18 and older in February 2022, and in adolescents aged 12-17 in August 2022.

Novavax submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged 18 and older in June 2022 and is awaiting a decision from the agency.